Becton Dickinson 'Capable Of Sustaining A Breakout', Analyst Upgrades Stock With 20% Upside Potential

  • KeyBanc has upgraded Becton, Dickinson, and Company BDX with a price target of $304.
  • The analyst writes that BDX is progressing toward increasing the overall WAMGR of its portfolio through increased new product introductions, bolt-on M&A, and portfolio rationalization. 
  • It has benefited from the excess revenue of its COVID-19 test, which it reinvested toward growth initiatives through FY22. 
  • The new launches are weighed toward high-growth end markets, and BDX estimates sales from FY21-FY25 new products could double to $1.7 billion in FY25 vs. $0.8 billion in FY21. 
  • The analyst does not expect transformative deals. Management is focused on scaled strategic bolt-ons of $1 billion- $3 billion. Its M&A strategy has been an upside driver of recent growth trends and has a decent pipeline of potential targets.
  • Finally, while timing is uncertain, Alaris's full reintroduction to market is a likely upside catalyst and incremental to its current growth profile over several years, the analyst writes.
  • BDX remains on track to achieve its operating margin target of 25% by FY25.
  • Its FY23 guidance implies a sizable sequential margin ramp with a 2H exit rate already close to its FY25 target, and if achieved, it could reinforce improving investor sentiment. 
  • For FY23, the company raised its revenue guidance to $19.1 billion-$19.3 billion compared to $18.6 billion-$18.8 billion previously announced. It is an adjusted EPS of $12.07-$12.32 compared to $11.85-$12.10 previously expected.
  • Price Action: BDX shares are up 0.36% at $253.90 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Large CapNewsUpgradesHealth CareAnalyst RatingsTrading IdeasGeneralBriefsExpert Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!